Because MLL-AF9 readily immortalizes human CD34+ cells, it is presumable that similar screenings may be carried out in the future using human MLL-AF9-transformed primitive progenitors, in order to test the candidate therapeutic agents in a system more closely related to the pathophysiology of human AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.